<DOC>
	<DOCNO>NCT02619994</DOCNO>
	<brief_summary>The purpose study compare efficacy 'new treatment regimen include delamanid , linezolid , levofloxacin , pyrazinamide nine twelve month ( investigational arm ) ' 'the standard treatment regimen include injectables 20 24 month ( control arm ) ' treat quinolone sensitive multidrug-resistant tuberculosis .</brief_summary>
	<brief_title>Treatment Shortening MDR-TB Using Existing New Drugs</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Males female age 19 85 year Confirmed Rifampicin resistance On current TB therapy ≤14 day time enrollment . Known quinoloneresistant MDRTB patient Known XDRTB patient Patients pregnant unwilling use proper contraceptive childbearing age Medical history galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption The need ongoing use prohibit drug study drug History optic neuropathy peripheral neuropathy People follow test result : i.Absolute neutrophil count &lt; 2000 cells/mL , ii.White blood cell count ( WBC ) &lt; 3.0 X 103/µL , iii.Hemoglobin &lt; 7.0 g/dL , iv.Serum creatinine &gt; 2.0 mg/dL , v.Aspartate aminotransferase ( AST SGOT ) &gt; 100 IU/L , vi.Alanine aminotransferase ( ALT SGPT ) &gt; 100 IU/L , vii.Total bilirubin &gt; 2.0 mg/dL , viii.Albumin &lt; 2.8g/dL , ix.QTcF &gt; 500ms History hypersensitivity reaction study drug</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>MDR tuberculosis</keyword>
	<keyword>linezolid</keyword>
	<keyword>delamanid</keyword>
	<keyword>Korea</keyword>
</DOC>